Scientific and clinical progress together with the development of effective novel therapeutic
options has engendered multiple important changes in the diagnosis and management of …

This is an update to the 2014 Canadian Hereditary Angioedema Guideline with an
expanded scope to include the management of hereditary angioedema (HAE) patients …

Hereditary Angioedema (HAE) is a rare and disabling disease for which early diagnosis and
effective therapy are critical. This revision and update of the global WAO/EAACI guideline on …

Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and
appropriate therapy are essential. This update and revision of the global guideline for HAE …

Angioedema is defined as localized and self‐limiting edema of the subcutaneous and
submucosal tissue, due to a temporary increase in vascular permeability caused by the …

Background Hereditary angioedema is a disabling, potentially fatal condition caused by
deficiency (type I) or dysfunction (type II) of the C1 inhibitor protein. In a phase 2 trial, the use …

This guidance for the management of patients with chronic urticaria and angioedema has
been prepared by the Standards of Care Committee of the British Society for Allergy and …

Hereditary Angioedema (HAE) is a rare disease and for this reason proper diagnosis and
appropriate therapy are often unknown or not available for physicians and other health care …

Hereditary angio-oedema is caused by a heterozygous deficiency of C1 inhibitor. This
inhibitor regulates several inflammatory pathways, and patients with hereditary angio …

Background The consensus documents published to date on hereditary angioedema with
C1 inhibitor deficiency (C1‐INH‐HAE) have focused on adult patients. Many of the previous …